Burns Therapeutics Pipeline Review H1 2015 Research Report

Dallas, TX -- (SBWire) -- 04/08/2015 --The report "Burns – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. Complete report available @ http://www.rnrmarketresearch.com/burns-pipeline-review-h1-2015-market-report.html.

Burns are among the most common household injuries, especially in children. Burns are characterized by severe skin damage in which many of the affected cells die. Burns are not static and may mature. Over a few hours a first degree burn may involve deeper structures and become second degree. Burns can cause swelling, blistering, scarring and, in serious cases, shock and even death. Burn symptoms can include Blisters, Pain, Peeling skin, Shock, Swelling, Red, white or charred skin, Coughing, Difficulty breathing, Voice changes, Wheezing and etc.

Companies discussed in this Burns – Pipeline Review, H1 2015 report include Adocia, AlgiPharma AS, Biogenomics Limited, Birken AG, CytoTools AG, Destiny Pharma Ltd., Fibrocell Science, Inc., HanAll Biopharma Co., Ltd., Kasiak Research Pvt. Ltd., Kuros Biosurgery AG, MediWound Ltd., Novan, Inc., Novartis AG, Se-cure Pharmaceuticals Ltd., Stemnion, Inc, Stratatech Corporation, USV Limited, Vida Therapeutics Inc., Xiber Science GmbH.

Drugs profiles discussed in this report includes albumin (human) (recombinant), Amnion Derived Cellular Cytokine Solution, azficel-T, bromelains, BVS-857, coagulation factor XIVa (human), Drug for Dermatology and Infectious Diseases, epidermal growth factor biosimilar, G-10, HL-156FIB, IMSP-001, KUR-212, Monoclonal Antibody Conjugated for Burns and Wounds, OleogelS-10, Oligomer G for Wounds And Burns, PEP-04, Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders, Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases, Refaheal, SC-106, Small Molecule for Chronic Wounds and Burns, StrataGraft Skin Tissue, V-2248, XF-70, Xib-1302. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=347015 . (This is a premium report priced at US$2000 for a single user License.)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Featured News & Press Releases cover by this report includes: Nov 03, 2014: MediWound Initiates Post-Marketing Study with NexoBrid to Treat Severe Burns in Pediatric Patients; Jul 16, 2014: MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health; May 12, 2014: MediWound Completes Recruitment of Commercial Management Team in Europe; May 08, 2014: MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica; Sep 23, 2012: Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid; Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting; Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting; Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.